(19) Europäisch s Patentamt
Eur pean Patent Office
Office uropé n des br v ts

(11) Publication number: **0 347 146 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication of patent specification: **01.09.93**

(51) Int. Cl.5: **C07D 471/04**, C07D 487/04, C07D 475/02, A61K 31/505, A61K 31/53, C07D 213/81, C07D 241/24, C07D 253/06, //(C07D471/04,239:00,221:00), (C07D487/04,241:00,239:00), (C07D487/04,253:00,239:00)

(21) Application number: **89305911.3**

(22) Date of filing: **12.06.89**

(54) Fused pyrimidine derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them.

(30) Priority: **16.06.88 GB 8814351**
16.06.88 GB 8814350
16.06.88 GB 8814353

(43) Date of publication of application:
20.12.89 Bulletin 89/51

(45) Publication of the grant of the patent:
01.09.93 Bulletin 93/35

(84) Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI LU NL SE

(56) References cited:
DE-A- 1 795 722
FR-A- 2 225 166
GB-A- 1 543 874

(73) Proprietor: **SMITH KLINE & FRENCH LABORATORIES LIMITED**
Mundells
Welwyn Garden City Hertfordshire, AL7 1EY(GB)

(72) Inventor: **Coates, William John**
SmithKline Pharmaceuticals, The Frythe, Welwyn, Hertfordshire AL6 9AR(GB)
Inventor: **Flynn, Sean Thomas**
SmithKline Pharmaceuticals, The Frythe, Welwyn, Hertfordshire AL6 9AR(GB)
Inventor: **Rawlings, Derek Anthony**
SmithKline Pharmaceuticals, The Frythe, Welwyn, Hertfordshire AL6 9AR(GB)

(74) Representative: **Waters, David Martin, Dr. et al**
Smith Kline & French Laboratories Ltd. Patent Department Mundells
Welwyn Garden City Hertfordshire AL7 1EY (GB)

EP 0 347 146 B1

Descriptl n

The present invention relates to fused pyrimidine derivatives, processes for their preparation, intermediates in their preparation, their use as therapeutic agents and to pharmaceutical compositions containing them. The compounds of this invention are inhibitors of a calmodulin insensitive cyclic GMP phosphodiesterase and are of use in combating such conditions where such inhibition is thought to be beneficial. They are bronchodilators and are therefore of use in combating chronic reversible obstructive lung diseases such as asthma and bronchitis. Some of the compounds of the present invention have anti-allergic activity and are therefore useful in combating allergic diseases such as allergic asthma, allergic rhinitis, urticaria and irritable bowel syndrome. Furthermore the compounds of this invention are vasodilators and are therefore of value in combating angina, hypertension and congestive heart failure.

GB-A-1,543,874 (Carlo Erba) discloses a series of substituted phenyl-3,4-dihydro-4-oxo-quinazoline derivatives which are said to possess anti-allergic activity.

FR-A-2,225,166 (Pfizer) discloses bicyclic and tricyclic ring systems containing a pyrimidine moiety as anti-allergic agents.

DE-A-1,795,722 (Karl Thomae) discloses substituted pyrimido[5,4-d]pyrimidines which act as cardiovascular agents.

Accordingly, the present invention provides compounds of the formula (1):



(1)

and pharmaceutically acceptable salts thereof, wherein

is a ring of sub-formula (a), (b), (c), (d), (e), (f) or (g) :



(a) (b) (c) (d)



(e) (f) (g)

R^1 is C_{1-6}alkyl, C_{2-6}alkenyl, C_{3-5}cycloalkylC_{1-6}alkyl, or C_{1-6}alkyl substituted by 1 to 6 fluoro groups;

R^2 is C_{1-6}alkylthio, C_{1-6}alkylsulphonyl, C_{1-6}alkoxy, hydroxy, hydrogen, hydrazino, C_{1-6}alkyl, phenyl, $-NHCOR^3$ wherein R^3 is hydrogen or C_{1-6}alkyl, or $-NR^4R^5$, wherein R^4 and R^5 together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino, hexahydroazepino, morpholino or piperazino ring, or R^4 and R^5 are independently hydrogen, C_{3-5}cycloalkyl or C_{1-6}alkyl which is optionally substituted by $-CF_3$, phenyl, $-S(O)_nC_{1-6}$-alkyl wherein n is 0, 1 or 2, $-OR^6$, $-CO_2R^7$ or $-NR^8R^9$ wherein R^6 to R^9 are independently hydrogen or C_{1-6}alkyl, provided that the carbon atom adjacent to the nitrogen atom is not substituted by said $-S(O)_nC_{1-6}$alkyl, $-OR^6$ or $-NR^8R^9$ groups; and

R is hydrogen and can also be hydroxy when R^2 is hydroxy.

Suitably R^1 is C_{2-5}alkyl for example ethyl, n-propyl, isopropyl, butyl, isobutyl or pentyl.

Suitably R^1 is C_{3-5}alkenyl for example propenyl, butenyl or pentenyl.

Suitably R^1 is cyclopropylmethyl.

Examples of C_{1-6}alkyl substituted by 1 to 6 fluoro groups include $-CF_3$, $-CH_2CF_3$ or $-CF_2CHFCF_3$.

Preferably R^1 is n-propyl.

Suitably R^2 is C_{1-6}alkylthio, C_{1-6}alkylsulphonyl or C_{1-6}alkoxy for example methylthio, ethylthio, methylsulphonyl, ethylsulphonyl, methoxy, ethoxy or propoxy.

Suitably R^2 is hydroxy, hydrogen or hydrazino.

Suitably R^2 is phenyl or C_{1-6}alkyl for example methyl, ethyl or propyl.

Suitably R^2 is $-NHCOR^3$ for example formamido or acetamido.

Suitably R^2 is $-NR^4R^5$ for example amino, methylamino, ethylamino, propylamino, dimethylamino, diethylamino, dipropylamino, cyclopropylamino, morpholino, 2,2,2-trifluoroethylamino, phenethylamino, 3-methylthiopropylamino, 3-methylsulphinylpropylamino, 3-methylsulphonylpropylamino, 2-hydroxyethylamino, 3-hydroxypropylamino, 2-hydroxypropylamino, 3-methoxypropylamino, N-ethyl-N-(2-hydroxyethyl)amino, 2-aminoethylamino, 2-dimethylaminoethylamino, ethoxycarbonylmethylamino, carboxymethylamino, 2-ethoxycarbonylethylamino or 2-carboxyethylamino.

Suitably

is a group of sub-formula (a) thus forming a pyrido[2,3-d]pyrimidine ring system.

Suitably

is a group of sub-formula (b) thus forming a pyrido[3,4-d]pyrimidine ring system.

Suitably

is a group of sub-formula (c) thus forming a pyrido[4,3-d]pyrimidine ring system.

Suitably

is a group of sub-formula (d) thus forming a pyrido[3,2-d]pyrimidine ring system.

Suitably

is a group of sub-formula (e) thus forming a pteridine ring system.

Suitably

is a group of sub-formula (f) thus forming a pyrimido[5,4-e][1,2,4]triazine ring system.

Suitably

is a group of sub-formula (g) thus forming a pyrimido[4,5-e][1,2,4]triazine ring system.

Particular compounds of this invention are :

2-(2-propoxyphenyl)pyrido[2,3-d]pyrimid-4(3H)-one,
2-(2-propoxyphenyl)pyrido[3,4-d]pyrimid-4(3H)-one,
2-(2-propoxyphenyl)pyrido[4,3-d]pyrimid-4(3H)-one,
2-(2-propoxyphenyl)pyrido[3,2-d]pyrimid-4(3H)-one,
2-(2-propoxyphenyl)pteridin-4(3H)-one,
2-(2-propoxyphenyl)pteridin-4,6(3H,5H)-dione,
2-(2-propoxyphenyl)pteridin-4,6,7(3H,5H,8H)-trione,
5,6-dihydro-3-methylthio-5-oxo-7-(2-propoxyphenyl)pyrimido[5,4-e][1,2,4]triazine,
3-amino-5,6-dihydro-5-oxo-7-(2-propoxyphenyl)pyrimido[5,4-e][1,2,4]triazine,
3-methylamino-5,6-dihydro-5-oxo-7-(2-propoxyphenyl)pyrimido[5,4-e][1,2,4]triazine,
3-methoxy-5,6-dihydro-5-oxo-7-(2-propoxyphenyl)pyrimido[5,4-e][1,2,4]triazine,
3-methylthio-8-oxo-6-(2-propoxyphenyl)-7,8-dihydropyrimido[4,5-e][1,2,4]triazine,
3-amino-8-oxo-6-(2-propoxyphenyl)-7,8-dihydropyrimido[4,5-e][1,2,4]triazine,
3-methylamino-8-oxo-6-(2-propoxyphenyl)-7,8-dihydropyrimido[4,5-e][1,2,4]triazine,
3-methoxy-8-oxo-6-(2-propoxyphenyl)-7,8-dihydropyrimido[4,5-e][1,2,4]triazine,